BioAmber closed a Series C funding round for $30 million, with Lanxess participating in the latter of two tranches with $10 million and joining the BioAmber board. Existing investors Naxos...
Contact us to learn the benefits of becoming a Lux member.
Or call us now
For North America (Boston Headquarters)
+1 (617) 502-5300
For EMEA (Amsterdam)
+31 20 280 7900
For APAC (Singapore)